User:Gmoney61/sandbox

In 1957, benactyzine was brought to market in the US by Merck Sharp & Dohme (a of division of Merck & Co) under the tradename "Suavitil".

In 1962, the Kefauver Harris Amendment was passed, amending the Federal Food, Drug, and Cosmetic Act to require drug manufacturers to provide proof of the effectiveness of their drugs before approval. The FDA implemented its Drug Efficacy Study Implementation (DESI) program to study and regulate drugs, including stanozolol, that had been introduced prior to the amendment. The DESI program was intended to classify all pre-1962 drugs that were already on the market as either effective, ineffective, or needing further study. The FDA enlisted the National Research Council of the National Academy of Sciences to evaluate publications on relevant drugs under the DESI program.

In 1970, the DESI review for benactyzine was completed and the NAS/NRC found that benactyzine was ineffective, and the FDA gave Merck Sharp & Dohme 6 months to provide additional research showing the drug's efficacy as an anxiety medication and physical relaxant. Two years later, the FDA removed Suavitil from the market due to lack of supporting evidence.